Juvederm

Juvederm is a brand of hyaluronic acid–based dermal fillers produced by Allergan Aesthetics, a division of AbbVie. The products are gels of hyaluronic acid cross-linked to form a stable matrix that restores volume and smooths wrinkles in facial skin. Most formulations are lidocaine-containing (XC) to reduce injection discomfort.

Different Juvederm formulations vary in density and cross-linking technology. Ultra and Ultra Plus lines use Hylacross; Voluma, Vollure, and Volbella use Vycross, which influences how the gel sits and how long it lasts. These design differences tailor results for specific facial regions and longevity.

Indications include soft tissue augmentation and contouring of the face. Common uses are filling nasolabial folds, marionette lines, and other wrinkles, lip augmentation, and enhancement of cheek volume. Specific products target different areas: Ultra XC for lips and mild-to-moderate wrinkles; Ultra Plus XC for deeper folds; Voluma XC for cheeks; Vollure XC for moderate-to-severe lines; Volbella XC for lips and lip lines.

Procedure and safety: Treatments are performed by trained clinicians in medical settings. Results are immediate and typically persist for multiple months, often 6–24 months depending on the product and area, with Voluma tending to last longer. Common side effects include temporary swelling, redness, tenderness, and bruising at the injection site; rare but serious risks include vascular occlusion. Juvederm is not recommended for everyone; discuss contraindications with a provider (such as pregnancy or active skin infection).

History and ownership: Juvederm was developed and marketed by Allergan; after Allergan’s acquisition by AbbVie, it remains under AbbVie’s Allergan Aesthetics division.